Skip to Content

Carafate (sucralfate) Disease Interactions

There are 2 disease interactions with Carafate (sucralfate):


Sucralfate (Includes Carafate) ↔ hypophosphatemia

Severe Potential Hazard, High plausibility. Applies to: Phosphate Imbalance

Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically. However, hypophosphatemia may occur in some patients, regardless of renal status. Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia. Monitoring phosphate levels in these patients is recommended.


  1. McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25
  2. "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  3. Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990): 291-5

Sucralfate (Includes Carafate) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment. Sucralfate must be used with caution in patients with chronic renal failure.


  1. Min DI, D'Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992): 636-9
  2. Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989): 179-81
  3. Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989): 674
  4. McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25
  5. Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987): 213-5
  6. Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989): 103-6
  7. "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.
View all 7 references

Carafate (sucralfate) drug interactions

There are 245 drug interactions with Carafate (sucralfate)

Carafate (sucralfate) alcohol/food interactions

There is 1 alcohol/food interaction with Carafate (sucralfate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.